Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

BACKGROUND: The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term safety and efficacy of treatments for a chronic diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy, Tannenbaum, Hyman, Patel, Neha P, Notter, Marianne, Sallstig, Peter, Reginster, Jean-Yves
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322990/
https://www.ncbi.nlm.nih.gov/pubmed/18328090
http://dx.doi.org/10.1186/1471-2474-9-32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322990/
https://www.ncbi.nlm.nih.gov/pubmed/18328090
http://dx.doi.org/10.1186/1471-2474-9-32

Ejemplares similares